Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing—remitting multiple sclerosis
Authors:
- Nicola De StefanoNSNicola De Stefano
- Claudio GasperiniCGClaudio Gasperini
- IMPROVE study investigatorsIIIMPROVE study investigators
- 3 March 2010
- journal article
- other
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 16 (7) , 888-892
Abstract
This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-β1a in relapsing—remitting multiple sclerosis (RRMS). Patients (n = 180) were randomized (2 : 1) to IFN-β1a or placebo for 16 weeks; all patients then received IFN-β1a for 24 weeks. Monthly brain MRI was performed. At week 16, the mean number of combined unique active (CUA) lesions was lower with IFN-β1a than with placebo (p < 0.001; 69% fewer lesions). The mean cumulative number of CUA lesions was already lower with IFN-β1a by week 4 (post hoc analysis; p = 0.015). The new formulation of sc IFN-β1a has rapid beneficial effects on MRI outcomes in RRMS.Keywords
This publication has 7 references indexed in Scilit:
- Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsMultiple Sclerosis Journal, 2008
- Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosisNeurology, 2008
- Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 2001
- Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosisJournal of Neurology, 2000
- Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosisAnnals of Neurology, 1999
- Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trialsJournal of the Neurological Sciences, 1999
- Rating neurologic impairment in multiple sclerosisNeurology, 1983